Project Grant W81XWH0710140

The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...

This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...

The Sloan-Kettering Institute for Cancer Research was awarded a $581,381 Project Grant by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The project aims to gain a better understanding of DNA damage repair pathways and how they go awry in cancer, with the goal of informing more effective therapeutic approaches. Specifically, the research will...

This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...

This Project Grant award of $524,815 was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Saint Louis University (SLU) on August 28, 2025. The grant supports research aimed at understanding the mechanisms of homologous recombination (HR), a DNA repair pathway critical for maintaining genomic stability. The key focus is on elucidating how mediator proteins and RAD51 paralogs facilitate the formation and stabilization of the RAD51 nucleoprotein...

This $517,090 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope supports innovative research aimed at understanding the role and function of a novel gene, A978, which is overexpressed in Philadelphia chromosome-positive and Philadelphia-like B-cell acute lymphoblastic leukemia (B-ALL). The key objectives of this 5-year project are to: 1) determine the biological effects of A978 in...

The National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) awarded a $3,201,530 Project Grant to the Sloan-Kettering Institute for Cancer Research to investigate the mechanisms underlying extrachromosomal DNA (ecDNA) segregation and repair in cancer. The key focus areas include: Exploring how the circular topology of ecDNA affects its function and maintenance, specifically examining the RNA-dependent physical tethering of ecDNA to mitotic chromosomes that facilitates...

This federal Project Grant award of $390,000.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to elucidate the mechanisms underlying DNA double-strand break repair at Thomas Jefferson University, doing business as Sidney Kimmel Medical College. The research aims to determine the regulatory mechanisms of the multi-protein and multi-step process required to coordinate the repair of DNA...

The U.S. National Institute of General Medical Sciences (NIGMS) awarded a $125,000 Project Grant under CFDA 93.859 (Biomedical Research and Research Training) to the University of California, Davis to investigate the role of the mismatch repair proteins MSH2 and MSH6 in maintaining genome stability. The 2-year project aims to delineate the mechanisms by which MSH2-MSH6 rejects mismatched recombination intermediates and determine the clinical significance of losing this activity in...

The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $445,000 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, awarded on January 22, 2025, supports DFCI's research on the molecular mechanisms of DNA double-strand break repair by homologous recombination, a critical process for cell survival and cancer prevention. The project aims to define the complex...